Pharmafile Logo
Pharmafocus logo
Advanced Search

Mepact

Showing 4 posts of 4 posts found.

NICE building

Mepact wins NICE backing

October 26, 2011
Research and Development, Sales and Marketing Mepact, NICE

NICE has recommended Takeda’s bone cancer drug Mepact after the firm offered a discount for the treatment. The watchdog’s final …

News

NICE recommends Takeda’s cancer drug Mepact

September 7, 2011
Sales and Marketing Mepact, NICE, Takeda

NICE has reversed its stance on Mepact and recommended the bone cancer drug after re-examining discounts and a new patient …

News

NICE unmoved on Takeda bone cancer drug

October 13, 2010
Sales and Marketing Mepact, NICE, Takeda

NICE has refused to recommend Takeda’s Mepact because of its “exceptionally high cost” and the “substantial uncertainty” about the osteosarcoma …

News

NICE rejects Takeda cancer drug over price concerns

July 12, 2010
Sales and Marketing Cancer, Mepact, NICE, Takeda, bone cancer

UK cost-effectiveness watchdog NICE has rejected Takeda’s orphan bone cancer drug Mepact due to concerns over price. In its draft …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025